NCT01394679 - A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Lung Cancer

Interventions

DRUG

(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)

One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG

DRUG

18 F FDG followed by PET/CT imaging

Single injection of 18 F FDG range of 10-20 mCi

Trial Locations (1)

62526

Decatur Memorial Hospital, Decatur